Tower Research Capital LLC (Trc) Halozyme Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 20,126 shares of HALO stock, worth $1.18 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
20,126
Previous 4,124
388.02%
Holding current value
$1.18 Million
Previous $235,000
309.36%
% of portfolio
0.02%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding HALO
# of Institutions
535Shares Held
122MCall Options Held
413KPut Options Held
154K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$778 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$389 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$238 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.07MShares$180 Million0.05% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.16B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...